We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Share this :
Print
GenScript MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit
GenScript MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit - GSCRPT (Additional S&H or Hazmat Fees May Apply)
List Price
$205.00
Your Price
$205.00
HOW MUCH YOU SAVE:
0.00 %
| NETA PART: | GSCRPT-A02291-40 |
| MFG.PART: | A02291-40 |
| UNSPSC: | 12352203 |
| Manufacturer: | GenScript USA Inc |
Overview
| Specificity | This product is specific for Mosunetuzumab and Cevostamab. |
| Host Species | Rabbit |
| Immunogen | Mosunetuzumab |
| Conjugate | Unconjugated |
Applications
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
| |||||||||
Properties
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for up to 1 year at -20 °C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification | Protein A affinity column |
| Isotype | Rabbit IgG, κ |
| Clonality | Monoclonal |
| Clone ID | 38A10 |
| Note | GenScript can customize this product per customers request including product size, buffer components, etc. |
Background
| Target Background | Mosunetuzumab is an innovative bispecific antibody that has a structure that resembles a natural human antibody, with two Fab regions. However, it differs from naturally-occurring antibodies as one Fab region targets CD20 and the other targets CD3. By recognizing and binding to these two different targets, Mosunetuzumab is able to redirect the cytotoxic activity of T-cells towards cancerous B-cells. This unique mechanism of action holds great potential for enhancing the effectiveness of cancer treatment. Cevostamab (BFCR4350A) is an innovative bispecific antibody, designed to engage T-cells and myeloma cells by targeting FcRH5 and CD3 receptors, respectively. Cevostamab possesses a unique structure with two Fab regions, with one specifically targeting FcRH5 and the other targeting CD3. This dual targeting mechanism activates the patients own T-cells and redirects them to eliminate myeloma cells expressing FcRH5 by releasing cytotoxic proteins. |
| Synonyms | Mosunetuzumab；MOSUNETUZUMAB；Mosunetuzumab-axgb；BTCT-4465A；BTCT 4465A；Lunsumio；RG 7828；RO7030816；Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody； Cevostamab；CEVOSTAMAB；BFCR 4350A; RG 6160; RO 7187797；Anti-FCRH5/CD3 BiTE Antibody |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
| SKU | GSCRPT-A02291-40 |
|---|---|
| Supplier Part Number | A02291-40 |
| UM | EA |
| UNSPSC | 12352203 |
| Manufacturer | GenScript USA Inc |
| ProductLine | GSCRPT |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.00 |
| Lead Time | 7 Business Days |
| Hazardous | N |